Suppr超能文献

派尔集合淋巴结和肠系膜淋巴结是BPO-KLH致敏小鼠中首次出现携带IgE的B淋巴细胞和半抗原特异性IgE抗体形成细胞的部位。

Peyer's patches and mesenteric lymph nodes are the sites of first appearance of IgE bearing B lymphocytes and hapten specific IgE antibody forming cells in BPO-KLH sensitized mice.

作者信息

Auci D L, Chice S M, Heusser C, Athanassiades T J, Durkin H G

机构信息

Department of Pathology, State University of New York Health Science Center, Brooklyn 11203.

出版信息

Reg Immunol. 1992 Jul-Aug;4(4):216-24.

PMID:1476874
Abstract

Antigen specific IgE responses originate in gut associated lymphoid tissue (GALT) of mice sensitized with benzylpenicilloyl-keyhole limpet hemocyanin (BPO-KLH) in alum, regardless of the route (intraperitoneal [i.p.], oral [gavage], subcutaneous [s.c.], intramuscular [i.m.] or intravenous [i.v.]) used for immunization. When BALB/c mice were injected i.p. with BPO-KLH (10 micrograms) in alum, B lymphocytes bearing membrane bound IgE (sIgE+B cells) first appeared simultaneously in Peyer's patches (PP) and mesenteric lymph node (MLN) on day 8. BPO specific IgE antibody forming cells (AFC) also appeared in PP on day 8, but were not found in MLN until day 10. On day 8, no sIgE+B cells or IgE AFC were found in bone marrow (BM) or other lymphoid organs. The appearance of sIgE+B cells and IgE AFC in PP and MLN was transient; these cells were no longer detected in PP on days 14 and 24, respectively, or in MLN on days 14 and 36, respectively. sIgE+B cells and IgE AFC did not appear in spleen until day 12, where they were detected through day 70. Although sIgE+B cells were never found in BM, IgE AFC appeared in BM on day 18, where they were detected through day 70. No sIgE+B cells or IgE AFC were found in other lymph nodes (OLN) on days 0-70. Boosting did not induce the reappearance of sIgE+B cells or IgE AFC in PP, the reappearance of sIgE+B cells in MLN, the appearance of sIgE+B cells in BM, or the appearance of sIgE+B cells or IgE AFC in OLN.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

抗原特异性IgE反应起源于用苄青霉素酰-钥孔戚血蓝蛋白(BPO-KLH)与明矾致敏的小鼠肠道相关淋巴组织(GALT),无论用于免疫的途径(腹腔内[i.p.]、口服[灌胃]、皮下[s.c.]、肌肉内[i.m.]或静脉内[i.v.])如何。当BALB/c小鼠腹腔内注射明矾中的BPO-KLH(10微克)时,携带膜结合IgE(sIgE+B细胞)的B淋巴细胞在第8天同时首次出现在派尔集合淋巴结(PP)和肠系膜淋巴结(MLN)中。BPO特异性IgE抗体形成细胞(AFC)在第8天也出现在PP中,但直到第10天才在MLN中发现。在第8天,骨髓(BM)或其他淋巴器官中未发现sIgE+B细胞或IgE AFC。PP和MLN中sIgE+B细胞和IgE AFC的出现是短暂的;这些细胞分别在第14天和第24天在PP中不再被检测到,或分别在第14天和第36天在MLN中不再被检测到。sIgE+B细胞和IgE AFC直到第12天才出现在脾脏中,并在那里被检测到直到第70天。虽然BM中从未发现sIgE+B细胞,但IgE AFC在第18天出现在BM中,并在那里被检测到直到第70天。在第0至70天,其他淋巴结(OLN)中未发现sIgE+B细胞或IgE AFC。加强免疫未诱导PP中sIgE+B细胞或IgE AFC的再次出现、MLN中sIgE+B细胞的再次出现、BM中sIgE+B细胞的出现或OLN中sIgE+B细胞或IgE AFC的出现。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验